Oramed Pharmaceuticals (ORMP) Common Equity (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Common Equity came in at $238.3 million in Q1 2026, up 70.33% YoY from $139.9 million in Q1 2025, and up 19.29% on a QoQ basis from $199.7 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Common Equity (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 16 years of Common Equity data on file, last reported at $238.3 million in Q1 2026.
- Quarterly Common Equity rose 70.33% year-over-year to $238.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $238.3 million (up 70.33% YoY) and the FY2025 annual result came in at $199.7 million, up 37.43% from the prior year.
- Common Equity rose to $238.3 million in Q1 2026, from $199.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $238.3 million in Q1 2026 to a low of $139.9 million in Q1 2025.
- A 5-year average of $165.2 million and a median of $153.6 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity decreased 15.58% — and 2026, when it soared 70.33%.
- Tracing ORMP's Common Equity over 5 years: stood at $151.2 million in 2022, then increased by 7.76% to $162.9 million in 2023, then retreated by 10.77% to $145.3 million in 2024, then soared by 37.43% to $199.7 million in 2025, then grew by 19.29% to $238.3 million in 2026.
- The last three Common Equity figures came in at $238.3 million (Q1 2026), $199.7 million (Q4 2025), and $203.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 317.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 317.47 Mn |
| Mar 31, 2026 | 238.28 Mn |
| Dec 31, 2025 | 199.74 Mn |
| Sep 30, 2025 | 203.28 Mn |
| Jun 30, 2025 | 153.58 Mn |
| Mar 31, 2025 | 139.89 Mn |
| Dec 31, 2024 | 145.35 Mn |
| Sep 30, 2024 | 155.52 Mn |
| Jun 30, 2024 | 176.15 Mn |
| Mar 31, 2024 | 165.72 Mn |
| Dec 31, 2023 | 162.89 Mn |
| Sep 30, 2023 | 148.23 Mn |
| Jun 30, 2023 | 150.66 Mn |
| Mar 31, 2023 | 150.15 Mn |
| Dec 31, 2022 | 151.16 Mn |
| Sep 30, 2022 | 153.15 Mn |
| Jun 30, 2022 | 153.04 Mn |
| Mar 31, 2022 | 162.22 Mn |
| Nov 30, 2021 | 170.16 Mn |
| Aug 31, 2021 | 116.52 Mn |